Tropic Biosciences develops gene-edited tropical crops via its proprietary GEiGS® platform, concentrating on banana and rice varieties designed for higher yields, increased disease resistance, and improved sustainability. In 2025 the company launched the first new banana varieties in more than 75 years, including a non-browning banana named one of TIME Magazine’s Best Inventions of 2025 and an extended shelf-life variety that increases green life by 12 days and can reduce waste by up to 50 percent. Tropic has made progress toward resistance to Panama Disease TR4 and shipped plants in 2025 to establish a mother plantation intended to support commercial deployment beginning in 2027. Demand for its new banana varieties has already surpassed supply, and the company has cited significant revenue growth as it scales. Tropic plans to expand its research across its rice portfolio and pursue additional high-impact, climate-resilient crops to address global food security and sustainability challenges.

Total raised

$179M

Funding rounds

4

Latest round

Series C

Latest activity

Mar 2026